Skip to main content
Previous
Poster Home
Next
BCG Refractory Non-Muscle Invasive Bladder Cancer Treated by Systemic Pembrolizumab is Associated with Discontinuation Due to Adverse Effects
07:30am - 03:35pm EST - April 6, 2024
Information
Resources
Author(s):
Borivoj Golijanin, BSc
, Miriam Hospital and Warren Alpert Medical School
Tags:
Clinical Oncology
Display Label
Action